Mural Oncology Plc (MURA) AI Stock Analysis

• Market Cap: $20.33M
• Dividend Yield: N/A
• Average Volume (3M): 281.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 116
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -7.58
• Shares Outstanding: 17,228,290
• 10 Day Avg. Volume: 669,434
• 30 Day Avg. Volume: 281,033
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 408.47% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

Mural Oncology Plc faces critical financial challenges with no revenue and high R&D expenses leading to significant losses. While technical indicators show a bearish trend, recent corporate developments provide some positive outlook through strategic focus and clinical advancements. However, the overall risk and lack of profitability result in a low stock score.

Positive Factors

Biologics License Application

MURA believes an objective response rate (ORR) of 20-25% would be a meaningful outcome and would support a discussion with FDA on a BLA submission for accelerated approval.

Mucosal Melanoma Data

Topline data from cohort 2 of ARTISTRY-6 remains on-track for a potentially registrational readout evaluating nemvaleukin monotherapy in patients with mucosal melanoma.

Negative Factors

Phase 3 Study Outcome

The interim analysis of the Phase 3 ARTISTRY-7 study failed to show a statistically significant overall survival benefit over investigator’s choice chemotherapy in platinum-resistant ovarian cancer.

Trial Discontinuation

MURA is discontinuing nemvaleukin's development in platinum-resistant ovarian cancer.

Mural Oncology Plc Business Overview & Revenue Model

Company Description

Mural Oncology Plc (MURA) is a biotechnology company specializing in the development and commercialization of innovative cancer therapies. The company focuses on leveraging cutting-edge research and technology to create targeted treatment options for various types of cancer. Mural Oncology aims to address unmet medical needs by providing advanced oncology solutions that enhance patient outcomes and improve quality of life.

How the Company Makes Money

Mural Oncology Plc generates revenue primarily through the development and commercialization of its oncology therapies. The company earns money by licensing its proprietary technologies and products to pharmaceutical companies and healthcare providers, receiving upfront payments, milestone payments, and royalties based on sales. Additionally, Mural Oncology may engage in strategic partnerships and collaborations with other biotech firms or research institutions, which can include joint development agreements and co-marketing arrangements. These partnerships can provide additional funding and resources to support the company's research and development efforts, contributing to its overall earnings.

Mural Oncology Plc Financial Statement Overview

Summary

Mural Oncology Plc has no revenue and high R&D expenses, leading to significant losses. While the company has a strong cash position and low debt, the continuous cash burn and lack of revenue generation present substantial financial risks.

Income Statement

Mural Oncology Plc has consistently reported zero revenue over the past years, indicating a lack of commercialization of its products. The company has incurred significant losses, with a net loss of $128.5 million in 2024. This reflects the high R&D costs typical in the biotechnology industry without offsetting revenue.

Balance Sheet

The company has a relatively healthy equity position with a stockholders' equity of $140.5 million as of 2024. However, it has a low debt-to-equity ratio due to minimal debt, which is a positive sign of low leverage. The high cash reserves provide a cushion, but the continuous net losses are concerning for long-term sustainability.

Cash Flow

Mural Oncology Plc has negative operating cash flow and free cash flow, indicating cash burn without incoming revenue. Despite this, the company raised significant capital in previous years, ensuring liquidity in the short term. However, the lack of cash flow generation from operations remains a significant risk.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	-2.57M	-1.54M	-1.47M
	EBIT
0.00	-194.64M	-195.15M	-175.37M
	EBITDA
0.00	-192.72M	-183.38M	-173.89M
	Net Income Common Stockholders
-128.51M	-207.45M	-200.03M	-175.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
144.38M	270.85M	-19.39M	-25.31M
	Total Assets
169.39M	301.75M	33.75M	35.11M
	Total Debt
8.02M	15.01M	19.39M	25.31M
	Net Debt
-107.44M	-255.84M	38.77M	50.61M
	Total Liabilities
28.89M	37.93M	55.41M	52.99M
	Stockholders Equity
140.50M	263.82M	-21.66M	-17.88M
Cash Flow		Free Cash Flow
-128.64M	-197.70M	-174.10M	-161.05M
	Operating Cash Flow
-128.54M	-194.25M	-168.59M	-156.67M
	Investing Cash Flow
-25.33M	-3.45M	-5.51M	-4.38M
	Financing Cash Flow
196.00K	468.81M	174.10M	161.05M

Mural Oncology Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MURA, the sentiment is Negative. The current price of 1.18 is below the 20-day moving average (MA) of 3.28, below the 50-day MA of 3.71, and below the 200-day MA of 3.47, indicating a bearish trend. The MACD of -0.56 indicates Positive momentum. The RSI at 17.03 is Positive, neither overbought nor oversold. The STOCH value of 1.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MURA.

Mural Oncology Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	80 Outperform	$10.27B	20.71	23.13%	―	18.49%	176.71%
Sector *	54 Neutral	$4.19B	-19.07	-13.11%	5.82%	26.04%	-78.69%
BNTX	54 Neutral	$22.79B	―	-3.38%	―	-27.64%	-172.62%
MRNA	48 Neutral	$12.01B	―	-28.77%	―	-52.75%	25.00%
KURA	45 Neutral	$569.32M	―	-42.91%	―	―	2.90%
ARVN	44 Neutral	$521.98M	―	-35.41%	―	-39.92%	7.38%
MURA	40 Underperform	$20.33M	―	-63.57%	―	―	―

Mural Oncology Plc Corporate Events

Mural Oncology Highlights 2024 Financial Results and Strategic Focus

On March 11, 2025, Mural Oncology announced its financial results for the fourth quarter and year-end 2024, highlighting a strategic focus on operational efficiency that extended their cash runway into Q1 2026. The company is preparing for significant clinical milestones in 2025, including interim data from the ARTISTRY-7 trial in ovarian cancer and top-line data from the ARTISTRY-6 trial in mucosal melanoma. These trials, involving their lead candidate nemvaleukin alfa, could impact Mural’s market positioning and offer potential value creation opportunities. Additionally, Mural expanded its pipeline with two new development candidates, MURA-8518 and MURA-7012, aimed at enhancing immune response and reducing toxicity.

Mural Oncology Advances Drug Pipeline and Extends Runway

Mural Oncology announced significant progress in its drug development pipeline, highlighting upcoming data readouts for its investigational therapy, nemvaleukin, in 2025. The company has extended its cash runway into Q1 2026 through operational efficiencies and plans to nominate new candidates and submit an IND for a phase 1 trial of MURA-8518 by Q4 2025. These developments position Mural Oncology as a key player in addressing unmet needs in cancer treatment, potentially benefiting patients and stakeholders with innovative therapies.